Improving Survival in Metastatic Urothelial Cancer

Improving Survival in Metastatic Urothelial Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Current Status of Therapy: Metastatic Urothelial Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 2: PD-L1 Expression in Metastatic Urothelial Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 3: Value of PD-L1 Testing in Metastatic Urothelial Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 4: Switch Maintenance Strategy for Metastatic Bladder Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 5: Increased Survival Outcomes with Switch Maintenance in mUC

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 6: Safety Data from JAVELIN Bladder 100

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 7: Practical Management of AEs in Metastatic Bladder Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 8: Changing the Standard of Care in Metastatic Bladder Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 9: Educating Patients on Maintenance Therapy in mUC

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 10: Metastatic Bladder Cancer: Progression After Maintenance

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 11: Sequencing Considerations in mUC after Frontline IO

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

EP. 12: Bright Future in Advanced Urothelial Cancer

ByShilpa Gupta, MD, Cleveland Clinic,Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Trending on OncLive

RP1 Plus Nivolumab Preserves Quality-Adjusted Survival in Advanced Melanoma After Anti–PD-1 Therapy

Afami-Cel Outcomes Are Tied to MAGE-A4 Expression, Tumor Burden in Synovial Sarcoma

STX-001 Produces Durable Systemic Responses in PD-1–Resistant Melanoma

VET3-TGI Generates Responses in Checkpoint Inhibitor–Refractory Cutaneous Cancers

JNJ-87189401 Plus Pasritamig Drives Deep PSA Responses With Favorable Safety in Pretreated mCRPC